Communiqués IO Biotech, Inc.

Actions

IOBT

US4497781090

Temps Différé Nasdaq Autres places de cotation 17:20:39 11/06/2024			Varia. 5j.	Varia. 1 janv.
1,25 ^USD	+0,81 %		+4,17 %	-33,51 %

15/05	IO BIOTECH, INC. : HC Wainwright réitère son opinion positive sur le titre	ZM
14/05	IO Biotech, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IO Biotech to Present at Jefferies Global Healthcare Conference	23/05	AQ
IO Biotech : Corporate Deck May 2024	17/05	PU
IO Biotech : Corporate Deck May 2024	14/05	PU
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights	14/05	AQ
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04	AQ
IO Biotech : Corporate Deck April 2024	17/04	PU
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness	15/04	AQ
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103	09/04	AQ
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer	05/04	AQ
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting	06/03	AQ
IO Biotech : Corporate Deck March 2024	05/03	PU
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results	05/03	AQ
IO Biotech to Present at 44th Annual Cowen Health Care Conference	26/02	AQ
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial	21/12	AQ
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12	AQ
IO Biotech Announces 2023 Third Quarter Results	13/11	AQ
IO Biotech Appoints Helen Collins, MD, to its Board of Directors	13/11	AQ
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma	10/11	AQ
IO Biotech Announces Participation in Upcoming Investor Conferences	08/11	AQ
IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	01/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués IO Biotech, Inc.

Actions

IOBT

US4497781090

Communiqués

Filtres